Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Consolidated Statements of Operations and Comprehensive Loss
Grant revenue	$ 285,759	$ 1,502,581
Operating expenses:
Research and development	7,043,035	9,363,537
General and administrative	6,476,560	6,458,699
Total operating expenses	13,519,595	15,822,236
Loss from operations	(13,233,836)	(14,319,655)
Other income (expense):
Interest income, net	652,086	1,289,144
Other income	77,500
Foreign currency (loss) gain	(95,319)	71,800
Total other income	634,267	1,360,944
Net loss	(12,599,569)	(12,958,711)
Other comprehensive loss:
Foreign currency translation	(7,335)	(16,106)
Total comprehensive loss	$ (12,606,904)	$ (12,974,817)
Net loss per share attributable to common stockholders, basic (in dollars per share)	$ (1.93)	$ (2.35)
Net loss per share attributable to common stockholders, diluted (in dollars per share)	$ (1.93)	$ (2.35)
Weighted-average common shares outstanding, basic (in shares)	6,538,722	5,509,921
Weighted-average common shares outstanding, diluted (in shares)	6,538,722	5,509,921